These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 24722935)

  • 1. [Iron deficiency in chronic heart failure: from diagnosis to therapy].
    von Haehling S; Anker SD
    Dtsch Med Wochenschr; 2014 Apr; 139(16):841-4. PubMed ID: 24722935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
    Okonko DO; Grzeslo A; Witkowski T; Mandal AK; Slater RM; Roughton M; Foldes G; Thum T; Majda J; Banasiak W; Missouris CG; Poole-Wilson PA; Anker SD; Ponikowski P
    J Am Coll Cardiol; 2008 Jan; 51(2):103-12. PubMed ID: 18191732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Iron deficiency anemia and anemia of chronic disease (ACD)].
    Hiller E
    Dtsch Med Wochenschr; 2014 May; 139(22):1163-70; quiz 1171-4. PubMed ID: 24809951
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy, safety and prognostic benefit of intravenous iron therapy with ferric carboxymaltose in patients with heart failure and left ventricular dysfunction.
    Robles-Mezcua A; González-Cruces N; Ruiz-Salas A; Morcillo-Hidalgo L; Robledo-Carmona J; Gómez-Doblas JJ; de Teresa E; García-Pinilla JM
    Int J Cardiol; 2016 Jan; 202():118-20. PubMed ID: 26397399
    [No Abstract]   [Full Text] [Related]  

  • 5. [Efficacy and tolerability of ferric carboxymaltose in geriatric patients with anemia. Data from three non-interventional studies].
    Röhrig G; Steinmetz T; Stein J; Geisel T; Virgin G; Schaefer R; Bach M; Schulz RJ
    MMW Fortschr Med; 2014 Jul; 156 Suppl 2():48-53. PubMed ID: 25351027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iron deficiency in heart failure.
    Dinatolo E; Dasseni N; Metra M; Lombardi C; von Haehling S
    J Cardiovasc Med (Hagerstown); 2018 Dec; 19(12):706-716. PubMed ID: 30222663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron substitution in the treatment of chronic heart failure.
    Gstrein C; Meyer M; Anabitarte P
    Swiss Med Wkly; 2017; 147():w14453. PubMed ID: 28695549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.
    van Veldhuisen DJ; Ponikowski P; van der Meer P; Metra M; Böhm M; Doletsky A; Voors AA; Macdougall IC; Anker SD; Roubert B; Zakin L; Cohen-Solal A;
    Circulation; 2017 Oct; 136(15):1374-1383. PubMed ID: 28701470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study.
    Viethen T; Gerhardt F; Dumitrescu D; Knoop-Busch S; ten Freyhaus H; Rudolph TK; Baldus S; Rosenkranz S
    Int J Cardiol; 2014 Aug; 175(2):233-9. PubMed ID: 24880481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the AFFIRM-AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure.
    Ponikowski P; Kirwan BA; Anker SD; Dorobantu M; Drozdz J; Fabien V; Filippatos G; Haboubi T; Keren A; Khintibidze I; Kragten H; Martinez FA; McDonagh T; Metra M; Milicic D; Nicolau JC; Ohlsson M; Parhomenko A; Pascual-Figal DA; Ruschitzka F; Sim D; Skouri H; van der Meer P; Jankowska EA
    Eur J Heart Fail; 2019 Dec; 21(12):1651-1658. PubMed ID: 31883356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heart failure in patients with kidney disease and iron deficiency; the role of iron therapy.
    Cases Amenós A; Ojeda López R; Portolés Pérez JM;
    Nefrologia; 2017; 37(6):587-591. PubMed ID: 28610806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Iron deficiency : a new target in treating chronic heart failure ?].
    Borgeaud M; Perrier A
    Rev Med Suisse; 2016 Oct; 12(535):1747-1751. PubMed ID: 28692214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost effectiveness of implementing ESC guidelines for treatment of iron deficiency in heart failure in the Nordic countries.
    Hofmarcher T; Cabrales Alin D; Linde C
    Scand Cardiovasc J; 2018 Dec; 52(6):348-355. PubMed ID: 30457358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.
    Ponikowski P; Filippatos G; Colet JC; Willenheimer R; Dickstein K; Lüscher T; Gaudesius G; von Eisenhart Rothe B; Mori C; Greenlaw N; Ford I; Macdougall I; Anker SD;
    Eur J Heart Fail; 2015 Mar; 17(3):329-39. PubMed ID: 25683972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of Ferinject assessment in patients with IRon deficiency and chronic Heart Failure (FAIR-HF) study: a randomized, placebo-controlled study of intravenous iron supplementation in patients with and without anaemia.
    Anker SD; Colet JC; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Mori C; von Eisenhart Rothe B; Pocock S; Poole-Wilson PA; Ponikowski P;
    Eur J Heart Fail; 2009 Nov; 11(11):1084-91. PubMed ID: 19875408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
    Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
    Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
    Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD
    Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in myocardial iron content following administration of intravenous iron (Myocardial-IRON): Study design.
    Miñana G; Cardells I; Palau P; Llàcer P; Fácila L; Almenar L; López-Lereu MP; Monmeneu JV; Amiguet M; González J; Serrano A; Montagud V; López-Vilella R; Valero E; García-Blas S; Bodí V; de la Espriella-Juan R; Sanchis J; Chorro FJ; Bayés-Genís A; Núñez J;
    Clin Cardiol; 2018 Jun; 41(6):729-735. PubMed ID: 29607528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemia.
    Geisser P; Banké-Bochita J
    Arzneimittelforschung; 2010; 60(6a):362-72. PubMed ID: 20648928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron deficiency and its management in patients undergoing lipoprotein apheresis. Comparison of two parenteral iron formulations.
    Schatz U; Arneth B; Siegert G; Siegels D; Fischer S; Julius U; Bornstein SR
    Atheroscler Suppl; 2013 Jan; 14(1):115-22. PubMed ID: 23357152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.